Weight gain

First-of-its-Kind Study from University of Exeter and Pvolve Researches Impact of Exercise on Women Pre and Post Menopause

Retrieved on: 
Wednesday, January 17, 2024
Health, Consumer, Women, Seniors, Fitness & Nutrition, General Health, Clinical Trials, Ageing, Woman, Facial muscles, Weight gain, Research, Heart, Sports medicine, University, Hip, Menopause, Risk, Quality of life, Love, Movement, Culture, Harvard University, Exercise, Brain, Metabolism, Body composition, Trial of the century, Dietary supplement

While women make up a large portion of the $100 billion global fitness market, they have historically been underrepresented in consumer research.

Key Points: 
  • While women make up a large portion of the $100 billion global fitness market, they have historically been underrepresented in consumer research.
  • In its Healthy Aging Study, Pvolve specifically addressed the physiological changes in aging women and the need to provide them with tailored exercise programs.
  • When engaged in a workout like Pvolve’s functional approach, the University of Exeter observed that women can experience many benefits.
  • Researchers found participants3 who consistently engaged in the Pvolve Method compared to a standard exercise routine4 noticed:
    The Healthy Aging study was conducted by the University of Exeter, which recruited 72 women aged 40-60 years old.

Recognize Healthy Weight Week by Incorporating Weight Support Supplement, Nucific Bio-X4, Into Your Routine

Retrieved on: 
Tuesday, January 23, 2024
Weight gain, Meal, Digestion, Weight loss, Diet, Probiotic, Lipase, Sale, Bloating, Fats, Human, Lactobacillus, Protein, Research, Metabolism, Dietary supplement

LOS ANGELES, Jan. 23, 2024 /PRNewswire/ -- Healthy Weight Week is the third week of every January and an annual observance that encourages individuals to adopt balanced lifestyle choices in support of a healthy body weight. But Dr. Amy Lee, a renowned expert in the field, suggests maintaining a healthy weight requires more than diet and exercise— optimizing your digestion is just as important. According to Dr. Lee, using a probiotic supplement can play a significant role in achieving and sustaining a healthy weight.

Key Points: 
  • LOS ANGELES, Jan. 23, 2024 /PRNewswire/ -- Healthy Weight Week is the third week of every January and an annual observance that encourages individuals to adopt balanced lifestyle choices in support of a healthy body weight.
  • But Dr. Amy Lee, a renowned expert in the field, suggests maintaining a healthy weight requires more than diet and exercise— optimizing your digestion is just as important.
  • According to Dr. Lee, using a probiotic supplement can play a significant role in achieving and sustaining a healthy weight.
  • Research suggests these factors can support a healthy metabolism, which can impact weight management.

Immunity Pharma Announces Positive Top Line Results from Phase 2a Trial with IPL344 in ALS Patients

Retrieved on: 
Wednesday, January 17, 2024
ACT, Death, Biomarker, Immunity, Pharma, Weight gain, Patient, SVC, ALS, Survival, Respiration, AFL, Risk, Aes, Plasma, Human, SAE, Pharmaceutical industry

Study suggests benefits in weight gain, respiration, and survival

Key Points: 
  • Study suggests benefits in weight gain, respiration, and survival
    JERUSALEM, Jan. 17, 2024 /PRNewswire/ -- Immunity Pharma , a clinical-stage neurology-focused biopharmaceutical company, today announced positive top line results from the Phase 2a trial with IPL344 in amyotrophic lateral sclerosis (ALS) patients.
  • IPL344 treated patients showed a mean slope of decline in ALSFRS-R of -0.53, equating 48% slower disease progression (p=0.028).
  • "These early-stage data support further development of IPL344 as a treatment for ALS, and merit further investigation in a large number of participants.
  • We intend to progress PL344 to a pivotal clinical trial in ALS," said Immunity's CEO, Eran Ovadia.

Your body already has a built-in weight loss system that works like Wegovy, Ozempic and Mounjaro – food and your gut microbiome

Retrieved on: 
Wednesday, January 17, 2024
Diabetes, Obesity, Flavonoid, Taste, Nutrient, Patient, Gastroparesis, Weight gain, Health, GIP, Depression, Addiction, Digestion, Food, Weight loss, Nausea, Sleep, Extrapyramidal system, Diet, Hormone, University, Pancreatitis, PYY, Constipation, Gastrointestinal tract, Movement, Disease, Splenic infarction, DSM-IV codes, Medicine, Carotenoid, Population, Diarrhea, Inflammation, Stroke, Stomach, Plant, Exercise, Overweight, Blood, Brain, Metabolism, Appetite, Vomiting, Cardiovascular disease, Pancreas, Polyphenol, Pharmaceutical industry

Wegovy, Ozempic and Mounjaro are weight loss and diabetes drugs that have made quite a splash in health news.

Key Points: 
  • Wegovy, Ozempic and Mounjaro are weight loss and diabetes drugs that have made quite a splash in health news.
  • They target regulatory pathways involved in both obesity and diabetes and are widely considered breakthroughs for weight loss and blood sugar control.
  • Here’s an inside-out perspective on the role natural gut hormones and healthy food play in metabolism and weight loss.

A broken gut

  • These include GLP-1, a natural version of Wegovy and Ozempic.
  • GLP-1 and other hormones like PYY help regulate blood sugar through the pancreas.
  • Prior to modern processed foods, metabolic regulatory pathways were under the direction of a diverse healthy gut microbiome that used these hormones to naturally regulate your metabolism and appetite.
  • Removal of these key food components and the resulting decrease in gut microbiome diversity may be an important factor contributing to the rise in obesity and diabetes.

A short track to metabolic health

  • Researchers have demonstrated their effectiveness at weight loss and blood sugar control.
  • These drugs complement other measures like gastric bypass surgery that are used in the most extreme cases of metabolic disease.
  • Medical guidelines support the use of new incretin-based medications like Wegovy, Ozempic and Mounjaro to manage the interrelated metabolic conditions of diabetes, obesity and cardiovascular disease.

A near-magic bullet – for the right folks


Despite the success and prospect of these drugs to help populations that may benefit most from them, current prescribing practices have raised some questions. Should people who are only a little overweight use these drugs? What are the risks of prescribing these drugs to children and adolescents for lifelong weight management?

  • These symptoms are related to how the drugs work to slow the gastrointestinal tract.
  • Other more severe, but rare, side effects include pancreatitis and irreversible gastroparesis, or inflammation of the pancreas and stomach paralysis.

All roads lead to lifestyle

  • Despite our greatest aspirations for quick fixes, it’s very possible that a healthy lifestyle remains the most important way to manage metabolic disease and overall health.
  • This includes regular exercise, stress management, sleep, getting outdoors and a balanced diet.


Christopher Damman is on the scientific advisory board at One BIO and Supergut.

Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia

Retrieved on: 
Tuesday, January 16, 2024
Schizophrenia, Patient, Weight gain, Dementia, Delusion, DSM-IV codes, Positive, SIGMAR1, Rett syndrome, Personalized medicine, Parkinson's disease, Alzheimer's disease, FDA, Therapy, Doctor of Philosophy, PANSS, Hallucination, Pharmaceutical industry

NEW YORK, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders, including Alzheimer's disease, Parkinson's disease, Rett syndrome, and schizophrenia, today announced the initiation of the U.S. FDA cleared placebo-controlled Phase 2 trial of ANAVEX®3-71 for the treatment of schizophrenia, which is expected to begin in Q2 2024. ANAVEX®3-71 positive initial Phase 1 results in healthy volunteers were previously reported.1

Key Points: 
  • ANAVEX®3-71 positive initial Phase 1 results in healthy volunteers were previously reported.1
    ANAVEX®3-71 (formerly AF710B) is a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator with agonistic effects.
  • As currently approved treatments only control a subset of symptoms, patients continue to exhibit severe impairments in social and occupational functioning and poor quality of life.
  • The placebo-controlled Phase 2 ANAVEX®3-71-SZ-001 study, will consist of two-parts to explore multiple ascending doses in individuals with schizophrenia followed by a 28-day treatment period in a larger cohort.
  • While current antipsychotic therapies can be effective in managing positive symptoms, like hallucinations and delusions, they may not fully address persistent negative symptoms or cognitive difficulties.

Ancera Unveils New Cutting-Edge Detection Tools to Support Productivity, Food Safety, and Interventional Efficacy in Poultry Industry

Retrieved on: 
Tuesday, January 16, 2024
Bird, Food safety, Supply, Weight gain, Total, Health, Command center, Wayfair, Sanitation, Food security, Poultry, Data science, Risk, Software, Quality control, Feces, National library, Clostridium perfringens, TVB, CSM, Microbiology, Poultry farming

BRANFORD, Conn., Jan. 16, 2024 /PRNewswire/ -- Today, Ancera, the innovator of supply chain intelligence, has announced the release of two new microbial detection tools designed to identify and enumerate Clostridium perfringens and Total Viable Bacteria (TVB) in poultry. Ancera's new cutting-edge assays will address critical challenges within the poultry industry, spanning both live operations and processing, in order to help companies increase productivity, food safety, and interventional efficacy.

Key Points: 
  • Ancera's new cutting-edge assays will address critical challenges within the poultry industry, spanning both live operations and processing, in order to help companies increase productivity, food safety, and interventional efficacy.
  • The Clostridium and TVB assays will double the number of novel assays on the PIPER platform," said Arjun Ganesan, CEO of Ancera.
  • "Retail customers see Clostridium perfringens as a productivity and animal welfare concern and our technology can help innovative poultry companies take action and gain market share.
  • According to The National Library of Medicine , Clostridium contributes to a $6 billion revenue loss for the global poultry industry.

Tonix Pharmaceuticals Presents Additional Data Highlighting the Favorable Tolerability and Differentiated Side Effect Profile of TNX-102 SL in Second Positive Phase 3 Clinical Trial for the Management of Fibromyalgia

Retrieved on: 
Tuesday, January 9, 2024
Fibromyalgia, Woman, Biotechnology, Hydrogen chloride, Patient, Weight gain, Sleep, Female, Fatigue, TNX-102, Quality of life, Food, NDA, Safety, Human, Tonix Pharmaceuticals, FDA, Tablet, Pain, New Drug Application, Gabapentinoid, Blood pressure

CHATHAM, N.J., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the presentation of additional safety and tolerability data from RESILIENT, the second positive Phase 3 study evaluating TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for the management of fibromyalgia, at Biotech Showcase™ 2024 in San Francisco, January 8-10.

Key Points: 
  • As previously announced, RESILIENT met its pre-specified primary endpoint, significantly reducing daily pain compared to placebo (p=0.00005) in participants with fibromyalgia.
  • Statistically significant and clinically meaningful results were also seen in all key secondary endpoints related to improving sleep quality, reducing fatigue, and improving overall fibromyalgia symptoms and function.
  • Tonix plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2024 for TNX-102 SL for the management of fibromyalgia.
  • RELIEF, the first Phase 3 trial of TNX-102 SL 5.6 mg in fibromyalgia, was completed in December 2020.

New Dog Care Book, "The Essential Guide Your Dog's Health Made Easy" by Veterinarian Cathrine Winblad Will Enhance the Joy of Dog Ownership

Retrieved on: 
Friday, January 5, 2024
Ebook, Oral hygiene, Infection, Pain, Companion, Nail, Health, Eating, Dog, Animal, Knowledge, Obesity, Food, Weight gain, Bacteria, Amazon, Exercise, Skin

TOENSBERG, Norway, Jan. 5, 2024 /PRNewswire/ -- As a dog owner, you've undoubtedly experienced the overwhelming joy and unconditional love that our canine companions bring into our lives. However, caring for a dog also comes with its challenges, from understanding their unique needs to navigating the complexities of veterinary care. Recognizing this need for clarity and guidance, veterinarian Cathrine Winblad unveils her new book, "Your Dog's Health Made Easy: 25 Essential Tips for a Happy and Healthy Companion."

Key Points: 
  • Recognizing this need for clarity and guidance, veterinarian Cathrine Winblad unveils her new book, "Your Dog's Health Made Easy: 25 Essential Tips for a Happy and Healthy Companion."
  • "As a pet owner myself, I understand the challenges and complexities of caring for a dog," says Dr. Cathrine Winblad.
  • Winblad's comprehensive guide "Your Dog's Health Made Easy" simplifies dog care, empowering readers to become responsible guardians.
  • Feed your dog a healthy diet: The food you feed your dog can have a big impact on their health.

How living like a hunter-gatherer could improve your health

Retrieved on: 
Thursday, January 4, 2024
Science, Survival, Jogging, Risk, Social support, Running, Movement, Plague, Mindfulness, Research, Prevalence, Nuclear family, Diet, Happiness, Health, Life, Fasting, Walking, Facial muscles, Cancer, Plant, Mental health, Cardiorespiratory fitness, Animal, Interval, Type 2 diabetes, Food, Fruit, Obesity, Dance, Weight gain, Longevity, Time, Cardiovascular disease, NHS, Nature, Hunting

Yet it’s often confusing to know the best way to achieve this, and many aspects of modern, westernised living conspire to keep us from achieving this goal.

Key Points: 
  • Yet it’s often confusing to know the best way to achieve this, and many aspects of modern, westernised living conspire to keep us from achieving this goal.
  • This suggests there’s much we can learn from hunter-gatherers to improve our lives.

Building connections

  • Each member contributes, shares equally and belongs to a collective greater than themselves.
  • According to James Woodburn, an anthropologist who studied the Hadza, tribe members “value their life as hunter-gatherers, they regard it as a wonderful life.
  • Many aspects of modern society, such as urbanisation, the nuclear family and consumerism, mean many of the connections inherent to hunter-gatherer society have been eroded.
  • Exercising in green spaces and practising mindfulness are also great ways of connecting with the present and boosting mental health.

Eating well

  • Diets primarily consist of plant-based foods, such as tubers, berries and fruit that are readily available.
  • Many studies have shown that plant-based diets and fasting can have many benefits for health.
  • Here's what the science says

    Because hunter-gatherers eat what nature offers, this means their diets consist mainly of whole foods.


Limiting intake of ultra-processed foods and adopting a diet more akin to those followed by hunter-gatherers can help improve your health.

Moving more

  • Their nomadic lifestyle of hunting and foraging meant they consistently covered distances from six to 16km daily.
  • Combined with diets high in ultra-processed foods, this means many of us consume more calories each day than we use, leading to weight gain.
  • We can also benefit from moving more like hunter-gatherers.
  • Making time to socialise, focusing on getting more plants in our diets and moving more often are all things we can do daily to live more like hunter-gatherers – and look after our health.
  • David Clayton has received research funding from the British Nutrition Foundation, the Society for Endocrinology, Innovate UK and the Turmeric Co. [email protected] currently receives funding from the National Institute for Health Research, the European Commission and the British Academy.
  • In the past, he has received grants from the Arts and Humanities Research Council, Economic and Social Research Council, UK Research and Innovation, Department for Health and Social Care and the National Health Service.

Newron Reports Exceptional One-year Results of Study 014/15 With Evenamide in Treatment-resistant Schizophrenia (TRS)

Retrieved on: 
Thursday, January 4, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Other Health, Psychiatry, XETRA, ADOS, Medication, Positive, Incidence, Clinical Global Impression, CNS, Molecular medicine, PANSS, EKG, Weight gain, Longevity, Peripheral nervous system, TRS, Patient, Pharmaceutical industry

The data demonstrated that treatment with evenamide was associated with sustained clinically significant benefit that increased throughout the one-year course of treatment.

Key Points: 
  • The data demonstrated that treatment with evenamide was associated with sustained clinically significant benefit that increased throughout the one-year course of treatment.
  • In contrast to common clinical experience, no patient “relapsed” during the one-year treatment period.
  • Ravi Anand, Newron’s Chief Medical Officer, said: “Treatment with evenamide as an add-on to antipsychotics in TRS patients has produced benefits that have never been reported before.
  • The presentation for this conference call can be downloaded as of today, January 4, 2024, at 7 am CET, on Newron’s website ( https://www.newron.com/investors/reports-and-presentation/year/2024 ).